Evaluation of Efficacy and Tolerability of Hizentra®
Status:
Unknown status
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the changes in the Treatment Satisfaction
Questionnaire for Medication in the areas of effectiveness, side effects, and convenience of
administration of each medication in Primary Immunodeficiency Disorder (PIDD) subjects
transitioning from subcutaneous Vivaglobin® to Hizentra®.